| ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer AJ Armstrong, RZ Szmulewitz, DP Petrylak, J Holzbeierlein, A Villers, ... Journal of Clinical Oncology 37 (32), 2974-2986, 2019 | 670 | 2019 |
| Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ... Clinical cancer research 21 (10), 2315-2324, 2015 | 458 | 2015 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 397 | 2021 |
| Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerctDNA and Resistance to AR-Targeted Therapy M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 384 | 2018 |
| Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ... JAMA oncology 2 (12), 1598-1606, 2016 | 319 | 2016 |
| PD-L1 is highly expressed in Enzalutamide resistant prostate cancer JL Bishop, A Sio, A Angeles, ME Roberts, AA Azad, KN Chi, A Zoubeidi Oncotarget 6 (1), 234, 2015 | 258 | 2015 |
| Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 … DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ... The Lancet Oncology 20 (12), 1730-1739, 2019 | 253 | 2019 |
| Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients N Lallous, SV Volik, S Awrey, E Leblanc, R Tse, J Murillo, K Singh, ... Genome biology 17, 1-15, 2016 | 191 | 2016 |
| Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients AA Azad, BJ Eigl, RN Murray, C Kollmannsberger, KN Chi European urology 67 (1), 23-29, 2015 | 183 | 2015 |
| A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel KN Chi, T Kheoh, CJ Ryan, A Molina, J Bellmunt, NJ Vogelzang, ... Annals of Oncology 27 (3), 454-460, 2016 | 147 | 2016 |
| Continuous flow deformability‐based separation of circulating tumor cells using microfluidic ratchets ES Park, C Jin, Q Guo, RR Ang, SP Duffy, K Matthews, A Azad, H Abdi, ... Small 12 (14), 1909-1919, 2016 | 135 | 2016 |
| Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis NJ Sathianathen, S Koschel, IA Thangasamy, J Teh, O Alghazo, ... European urology 77 (3), 365-372, 2020 | 127 | 2020 |
| AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate T Todenhöfer, A Azad, C Stewart, J Gao, BJ Eigl, ME Gleave, AM Joshua, ... The Journal of urology 197 (1), 135-142, 2017 | 121 | 2017 |
| Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in … AJ Weickhardt, TJ Price, G Chong, V Gebski, N Pavlakis, TG Johns, ... Journal of clinical oncology 30 (13), 1505-1512, 2012 | 111 | 2012 |
| Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab HK Gan, A Azad, L Cher, PLR Mitchell Neuro-oncology 12 (2), 212-215, 2010 | 111 | 2010 |
| Targeting heat shock proteins in metastatic castration-resistant prostate cancer AA Azad, A Zoubeidi, ME Gleave, KN Chi Nature reviews Urology 12 (1), 26-36, 2015 | 109 | 2015 |
| TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer … MS Hofman, L Emmett, J Violet, A Y. Zhang, NJ Lawrence, M Stockler, ... BJU international 124, 5-13, 2019 | 98 | 2019 |
| Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel HH Cheng, R Gulati, A Azad, R Nadal, P Twardowski, UN Vaishampayan, ... Prostate cancer and prostatic diseases 18 (2), 122-127, 2015 | 92 | 2015 |
| Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps X Qin, S Park, SP Duffy, K Matthews, RR Ang, T Todenhöfer, H Abdi, ... Lab on a Chip 15 (10), 2278-2286, 2015 | 90 | 2015 |
| Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer AJ Armstrong, AA Azad, T Iguchi, RZ Szmulewitz, DP Petrylak, ... Journal of Clinical Oncology 40 (15), 1616, 2022 | 81 | 2022 |
Kim N. ChiProfessor of Medicine, University of British ColumbiaVerified email at bccancer.bc.ca
